Viatris Inc. (VTRS) News
Follow Viatris Inc. (VTRS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 34 public stories across 21 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Viatris Reports Third-Quarter Revenue of $3.75B, EPS Loss of $0.28
Revenue was essentially flat year over year as Viatris’ net loss widened. Stronger sales in Greater China and North America, including new products and estradiol transdermal products, were offset by base-business erosion
EQUITY | Nov 05, 2026, 02:31 PM UTC
M
Viatris Reports Q3 Loss of $325.3 Million, Raises 2026 Guidance
Viatris reported a third-quarter net loss of $325.3 million, compared with a $128.2 million loss a year earlier, and EPS of -$0.28. It raised its full-year 2026 guidance.
EQUITY | Nov 05, 2026, 12:32 PM UTC
M
Viatris Reports Q3 Revenue of $3.75B, Below FactSet Estimate
Viatris reported Q3 revenue of $3.75 billion, versus a FactSet estimate of $3.79 billion.
EQUITY | Nov 05, 2026, 12:32 PM UTC
M
Viatris Raises 2026 Adjusted EBITDA View to $4.45B-$4.55B
EARNINGS | Nov 05, 2026, 12:04 PM UTC
M
Viatris raises 2026 adjusted EPS view to $2.56-$2.63
EARNINGS | Nov 05, 2026, 12:03 PM UTC
M
Viatris Narrows 2026 Revenue View to $14.7B–$14.9B
EARNINGS | Nov 05, 2026, 12:03 PM UTC
M
Viatris Commences Tender Offer to Acquire Pacira BioSciences
EQUITY | Oct 30, 2026, 01:03 PM UTC
M
US Estrogen Shortage Worsens as Demand Shifts to Alternatives
Pharmacies report supply problems with estrogen injections and vaginal creams. Viatris has added shifts at its Vermont plant and plans an additional production line to meet demand.
EQUITY | Oct 28, 2026, 10:05 AM UTC
M
FDA Approves Viatris’ Ryzumvi for Presbyopia Treatment
Viatris said the U.S. FDA approved Ryzumvi for the treatment of presbyopia.
REGULATION | Oct 16, 2026, 10:08 PM UTC
L
Viatris Receives FDA Approval for RYZUMVI Presbyopia Treatment
The FDA approved Viatris’ RYZUMVI (phentolamine ophthalmic solution 0.75%) for treating presbyopia in adults.
REGULATION | Oct 16, 2026, 08:06 PM UTC
M
Viatris Agrees to Buy Pacira BioSciences for $1.65 Billion
Viatris said it agreed to acquire Pacira BioSciences for $1.65 billion in cash.
MNA | Oct 12, 2026, 06:32 AM UTC
H
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
New On The Block Caribou Biosciences, Inc. (NASDAQ: CRBU ), a clinical-stage CRISPR genome-editing biopharmaceutical company, is exploring strategic alternatives to maximize stockholder value and plans to discontinue fur
LIVE | Oct 09, 2026, 07:03 PM UTC
H
Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Viatris Inc. (NASDAQ: VTRS ) announced Thursday that it agreed to acquire Pacira BioSciences Inc. (NASDAQ: PCRX ) for $1.65 billion, strengthening its position in non-opioid pain management. Under the agreement, Viatris
LIVE | Oct 08, 2026, 04:49 PM UTC
M
Pacira to pay Viatris $62 million termination fee
Pacira BioSciences will pay Viatris a $62 million termination fee under specified circumstances, per the reported agreement terms.
EQUITY | Oct 08, 2026, 01:04 PM UTC
M
Viatris agrees to acquire Pacira BioSciences
EQUITY | Oct 08, 2026, 11:56 AM UTC
M
Viatris to report third-quarter 2026 financial results on November 5, 2026
EQUITY | Oct 05, 2026, 10:59 AM UTC
L
Weekly Recap: Wegovy patent non-infringement suit and $25 Oppenheimer PT
Viatris, Inc. (NASDAQ:VTRS) is challenging Novo Nordisk in Delaware, suing for a declaratory judgment that its proposed generic Wegovy doesn’t infringe the single—dose pen method patent, as Oppenheimer pegs VTRS at a $25
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Mylan asks US court to clear Wegovy generic from Novo patent claims
By Blake BrittainGeneric drugmaker Viatris NASDAQ:VTRS has sued Danish pharmaceutical giant Novo Nordisk OMXCOP:NOVO_B in Delaware federal court, seeking a ruling that its proposed generic of Novo's blockbuster GLP-1 dru
NEWS | Sep 25, 2026, 07:19 PM UTC
L
Viatris Price Target Announced at $25.00/Share by Oppenheimer
Ratings actions from Benzinga
NEWS | Sep 23, 2026, 12:15 PM UTC
H
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. re
LIVE | Sep 23, 2026, 11:05 AM UTC
L
VTRS - Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
VTRS - Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome
NEWS | Sep 16, 2026, 10:59 AM UTC
L
Viatris initiated at Outperform, $20 price target by Leerink
Leerink Partners initiated coverage on Viatris with an Outperform rating and a $20.00/share price target.
EQUITY | Sep 09, 2026, 03:53 PM UTC
L
Viatris price target lifted to $20 by Argus Research
Argus Research raised its price target on Viatris to $20.00 per share from $15.00, according to ratings actions cited by Benzinga (via TradingView News).
EQUITY | Sep 08, 2026, 01:00 PM UTC
M
Roivant drug meets mid-stage goals; ROIV shares jump premarket
Roivant (ROIV) said its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
EQUITY | Sep 08, 2026, 10:59 AM UTC
H
Viatris Sharpens Focus with Divestiture, Hikes 2026 Outlook
Harrow Inc. (NASDAQ: HROW ) on Thursday agreed to acquire Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. (NASDAQ: VTRS ). Viatris To Sell Tyrvaya To Harrow In Up To $100 Million Deal Tyrvaya is a ch
EARNINGS | Aug 06, 2026, 05:56 PM UTC
H
VTRS Beats Revenue Estimates
VTRS reports $3.8B revenue, beating estimates
EARNINGS | Aug 06, 2026, 11:05 AM UTC
H
Viatris Raises FY2026 Adj EPS Guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 Est; Raises FY2026 Sales Guidance from $14.450B-$14.950B to
Viatris (NASDAQ: VTRS ) raises FY2026 Adj EPS guidance from $2.33-$2.47 to $2.45-$2.49 vs $2.44 analyst estimate. Raises FY2026 sales outlook from $14.450 billion-$14.950 billion to $14.550 billion-$14.950 billion vs $14
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
VTRS VTRS - Viatris Reports Second-Quarter 2026 Financial Results
VTRS VTRS - Viatris Reports Second-Quarter 2026 Financial Results
EQUITY | Aug 06, 2026, 10:59 AM UTC
L
Viatris Announces Quarterly Dividend
Viatris declares quarterly dividend
EQUITY | Aug 04, 2026, 11:00 AM UTC
L
VTRS VTRS - Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
VTRS VTRS - Viatris Receives U.S. FDA Approval for Gwyn Lo™, a Once-Weekly Contraceptive Patch
REGULATION | Jul 29, 2026, 10:59 AM UTC
L
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
AMRX TEVA favored names in generics and neutral on VTRS in Q2 preview @ GSCO
EQUITY | Jul 22, 2026, 12:51 PM UTC
L
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for remainder of month: --ELVT expected around 7/23 – Drug rivoceranib + camrelizum
EQUITY | Jul 20, 2026, 05:31 PM UTC
L
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout. re
RATES | Jul 14, 2026, 11:30 AM UTC
H
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Analysts' ratings for high-yielding health care stocks: Viatris, Medtronic, and GSK.
EQUITY | Jun 29, 2026, 11:46 AM UTC